2Q Financial Markets Preview

2Q Preview: News flow comes later

If the first quarter was light on stock-moving milestones, companies and investors are unlikely to get any relief until the second half of the year. But then much of that news should be fairly consequential.

Amgen Inc. (AMGN, Thousand Oaks, Calif.) is hoping for three U.S. product launches this year, including Aranesp darbepoetin alfa to treat anemia resulting from chronic renal failure, which received European approval last month (see BioCentury, March 26). AMGN's approval calendar also has Kineret IL-1ra recombinant anti-inflammatory protein to treat rheumatoid arthritis; and Abarelix depot